Inhibikase Therapeutics, Inc. (IKT) — Net Income
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | -$48.26M | -75.4% |
| 2024 | -$27.52M | -44.6% |
| 2023 | -$19.03M | -5.4% |
| 2022 | -$18.05M | -22.1% |
| 2021 | -$14.79M | -419.2% |
| 2020 | -$2.85M | — |
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | -$48.26M | -75.4% |
| 2024 | -$27.52M | -44.6% |
| 2023 | -$19.03M | -5.4% |
| 2022 | -$18.05M | -22.1% |
| 2021 | -$14.79M | -419.2% |
| 2020 | -$2.85M | — |